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Abstract
Background: Infections and immunological processes are likely to be involved in the pathogenesis of Tourette’s
syndrome (TS). To determine possible common underlying immunological mechanisms, we focused on innate
immunity and studied markers of inflammation, monocytes, and monocyte-derived cytokines.
Methods: In a cross-sectional study, we used current methods to determine the number of monocytes and levels
of C-reactive protein (CRP) in 46 children, adolescents, and adult patients suffering from TS and in 43 healthy
controls matched for age and sex. Tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), soluble CD14
(sCD14), IL1-receptor antagonist (IL1-ra), and serum neopterin were detected by immunoassays.
Results: We found that CRP and neopterin levels and the number of monocytes were significantly higher in TS
patients than in healthy controls. Serum concentrations of TNF-alpha, sIL1-ra, and sCD14 were significantly lower in
TS patients. All measured values were within normal ranges and often close to detection limits.
Conclusions: The present results point to a monocyte dysregulation in TS. This possible dysbalance in innate
immunity could predispose to infections or autoimmune reactions.
Background
Tourette`s syndrome (TS) is a neuropsychiatric disorder
that is characterized by childhood onset of multiple motor
tics and at least one vocal tic. The disease shows exacerba-
tions and remissions over time. Obsessive-compulsive dis-
order (OCD), attention deficit hyperactivity disorder
(ADHD), mood disorders, and behavioral problems are
often associated with TS [1]. TS can lead to social impair-
ment, psychological distress, and discrimination; extreme
forms of this disorder include self-injurious motor tics and
coprolalia. Epidemiological studies show that TS is rela-
tively common, with an estimated overall worldwide
prevalence of 1% [2] and an even higher prevalence among
children. Boys are affected about 4 times more often than
girls [3]. The results of different studies point to a multi-
factorial pathogenesis of TS, with an interaction of genetic,
environmental, hormonal, and immunological factors [4].
The exact pathogenic mechanisms are still unclear, but a
disturbed dopaminergic neurotransmission in the basal
ganglia-striato-thalamo-cortical circuits seems to generate
tic expression as a common endpoint. Genetics play also
an important role in the disease etiology of TS. However,
TS is likely to be genetically heterogeneous and until now
no loci have been definitely confirmed. Twin studies sup-
port a significant role for non-genetic influences [5].
One important hypothesis is that infections could trig-
ger the onset of TS or tic exacerbations. Signs of acute
or chronic infections have been observed in TS patients
[6]. As both acute infections with A beta-hemolytic
streptococcus (GABHS) [7,8] and poststreptococcal in-
flammation [9] have been reported to be associated with
TS, TS has been proposed to be one of the pediatric
autoimmune neuropsychiatric disorders associated with
streptococcal infection (PANDAS) [10,11], similar to the
pathophysiological model of Sydenham’s chorea. More-
over, increased streptococcal antibodies and signs of in-
flammation have been observed in adult TS patients
[12,13]. Nevertheless, the topic of PANDAS is conten-
tious, and it is not clear whether it is a distinct clinical
entity [14]. Also, infections with Borellia burgdorferi
[15], acute or chronic infections with Mycoplasma
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reported to trigger tic exacerbations. Recently, we could
report significantly more positive IgG antibody titers
against Chlamydia trachomatis in TS patients than in
healthy controls and a trend to higher antibody titers of
Toxoplasma gondii in TS patients [17]. Both pathogens can
invade the brain parenchyma. The role of autoantibodies
against neuronal structures in TS is still controversial, and
the causality is not proven; however, autoantibodies against
neuronal structures could be one possible pathophysio-
logical model for a subgroup of TS patients.
Another important hypothesis is the existence of a com-
mon underlying altered immune status that results in an
insufficient clearing of infectious agents and triggers the
onset of TS or worsening of tics. The innate immune sys-
tem in particular is important for the first immune re-
sponse. For this reason, we investigated monocytes; the
mainly monocyte-derived cytokines tumor necrosis factor
alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1
receptor-antagonist (IL1-ra); and monocyte-derived sol-
uble CD14 (sCD14). Cells of the monocyte/macrophage
lineage phagocytize foreign material, present antigens to
T-cells and produce proinflammatory cytokines, such as
TNF-alpha, IL-1, and IL-6. Peripheral cytokines are known
to be able to cross the blood–brain barrier and influence
neuronal brain functions, even in low concentrations [18].
To our knowledge, so far no studies have focused mainly
on monocytes and monocyte-derived parameters in TS
and only a few studies have investigated the role of cyto-
kines in TS. Leckman et al. [19] reported increased serum
levels of TNF-alpha and IL-12 in juvenile TS patients. This
is an interesting finding, because in OCD decreased levels
of TNF-alpha were described [20-22]. Since OCD and TS
show a high rate of co-morbidity [23], it would be of inter-
est to find a possible discriminative marker (e.g. cytokines
that are decreased in OCD and increased in TS) for the
two disorders. Gabbay et al. investigated juvenile TS
patients and reported higher IL-12 plasma levels in TS/
OCD patients than in controls and higher IL-2 in the sub-
group of TS/OCD patients than in TS patients without
OCD [24]. Bos-Veneman et al. [25] did not evaluate find-
ings of an immune activation or differences between TS
and controls, but did find that serum IL-2 concentrations
were positively associated with tic severity ratings.
Soluble CD14 plays an important role in innate im-
munity. Monocytes carry the surface marker CD14, a
membrane-bound or soluble glycoprotein that mediates
the interaction of lipopolysaccaride (LPS; a component
of the cell surface of gram-negative bacteria) and of
lipoteichoic acid (LTA; a component of different gram-
positive bacteria) with cells. Mycoplasma pneumoniae
can also be recognized by LPS-binding protein [26].
S o l u b l eC D 1 4a d d i t i o n a l l ye n h a n c e st h ei m m u n er e -
sponse to LPS in cell types that lack the CD14 receptor
on their surface [26], i.e. sCD14 is a co-activator for
many cell types in the cascade of immune activation in
response to a monocytic signal [27,28]. Decreased
sCD14 levels point to a decreased state of monocyte ac-
tivation. It has been postulated that sCD14 is important
for the development of the T cell subset balance [29].
Reduced sCD14 levels in breast milk have been reported
to be associated with the occurrence of atrophy and
eczema [30]. So far, sCD14 has not been investigated
in TS patients. Recently, reduced natural regulatory T
(Tregs) cells in children with TS or OCD or both
were reported, indicating a predisposition for overriding
autoimmune responses [31].
To detect a possible (chronic) inflammatory state in
TS patients, we measured neopterin and C-reactive pro-
tein (CRP), the most common and sensitive markers for
an inflammatory process.
The study focused on innate immunity, because distur-
bances in innate immunity could explain an increased
susceptibility to infectious agents.
Methods
In a cross-sectional study performed at the Department of
Psychiatry and Psychotherapy, Ludwig Maximilian Univer-
sity (LMU), Munich, Germany, we examined 46 TS
patients and 43 age- and sex-matched healthy controls. All
46 TS patients fulfilled the DSM-IV-TR diagnostic criteria
[32] for TS. Diagnoses were made by two independent
experienced psychiatrists. Tic severity was quantified with
the Tourette’s Syndrome Global Scale (TSGS) [33], and
co-morbid OCD with the Maudsley Obsessive-Compulsive
Inventory (MOCI) [34]. As a cut-off value for the group
with OCD, study participants with a MOCI value of≥12
were chosen (maximum value 30 points) [35]. The mean
duration of TS was 21.1 years. The 43 healthy controls
were recruited from the general population in Munich by
advertisements. An experienced psychiatrist performed
structured clinical interviews to exclude any psychiatric
disorders. Exclusion criteria for patients and healthy con-
trols were acute infections and immunological, neuro-
logical, or other medical disorders and were checked by
assessing the medical history, clinical examination, and la-
boratory measurements (CRP, differential blood count,
basic parameters of clinical chemistry). No treatment with
corticosteroids or other immune-modulating agents was
allowed. All study participants were Caucasians. Written
informed consent was obtained from all study participants.
If study participants were younger than 18 years, at least
one parent had to give informed consent. The study was
approved by the ethics committee of the LMU medical
faculty.
A total of 18 ml blood was drawn from each participant:
3 ml EDTA blood was used for the differential blood
count; 7.5 ml heparin blood, to determine CRP and basic
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parameters, TSH); and 7.5 ml whole blood, to extract
serum for later immunoassays. Within 30 minutes after
vein puncture, 7.5 ml whole human blood was centrifuged
at 3500 rpm at 4°C for 10 minutes and the extracted serum
was aliquoted and stored at −80°C for later measurements.
The differential blood count included a monocyte count
and was performed on a hematology analyzer (Coulter
STKS). CRP and basic clinical chemistry parameters were
measured on an automated analyzer (ROCHE, Hitachi
912). To detect TNF-alpha and IL-6, we used the Bio-Plex
cytokine assay and the cytokine reagent and diluent kit
(Bio-Rad, Munich). The Bio-Plex system combines the
principle of a sandwich immunoassay with Luminex fluor-
escent bead technology. The lower limits of detection were
0.2 pg/ml for TNF-alpha and 1.7 pg/ml for IL-6. sCD14
was detected in serum by using the Quantikine soluble
CD14 Immunoassay (R&D Systems, Minneapolis), with a
lower limit of detection of 0.25 ng/ml. Neopterin was mea-
sured with the neopterin solid phase enzyme-linked im-
munosorbent assay (IBL, Hamburg); the lower detection
limit was 1.35 nmol/l . For IL1-ra, we used the Quantikine
IL1-ra Immunoassay (R&D Systems, Minneapolis) with a
lower limit of detection of 0.047 ng/ml. All assays were
done according to the respective manufacturer’s instruc-
tions for use.
We used the SPSS 13.0.1. statistic program for statistical
analysis. Data are given in means±standard deviation (SD).
Since some data did not pass the Kolmogorov-Smirnov test
for normality, Mann–Whitney U tests were used to test
differences between the patient and healthy control groups.
P-values below alpha≤0.05 were considered significant,
and all tests were two-tailed. As the analyses were explora-
tory in nature and the monocyte-derived products seemed
to be highly correlated, we did not correct for multiple
tests. Results have to be interpreted accordingly. In
addition, the results were analyzed by Kruskal-Wallis
ANOVA and alpha-corrected post hoc Mann–Whitney U
tests. Pearson’s correlation coefficients were calculated to
test for possible correlations, and proportional data were
analyzed by using Fisher’s exact test to test for homogen-
eity in the two groups.
Results
Study demographics
We found no significant differences between the two
groups concerning age (χ(2)
2 =1.16, p=0.60) or gender
(χ(1)
2 =0.83, p=0.47). Demographic data are summarized
in Table 1.
The medical history and basic clinical chemistry para-
meters showed no signs of any serious diseases, includ-
ing hypo- or hyperthyreosis or acute infections, in either
TS patients or healthy controls.
Immune markers in Tourette’s syndrome
The mean number of monocytes/nl blood, CRP levels,
and serum neopterin concentration were all significantly
higher in TS patients than in healthy controls. However,
these levels were within normal ranges in both groups.
In contrast, the mean serum TNF-alpha concentration
was significantly lower in TS patients than in healthy
controls. IL-6 serum levels showed no differences be-
tween groups. Mean serum concentrations of sCD14 and
mean IL1-ra concentrations were significantly lower in
TS patients (see Table 2).
Subgroup analyses of TNF-alpha, IL1-ra, sCD14, and
neopterin did not reveal any differences between non-
medicated and medicated TS patients. Similarly, no dif-
ferences were seen between TS patients with and those
without co-morbid OCD. Interestingly, the subgroup
analyses revealed stronger differences in the comparison
between TS patients with co-morbid OCD and healthy
controls. These findings are shown in Table 3.
Analyses of TNF-alpha, sCD14, IL1-ra, and neopterin
for age subgroups are summarized in Table 4. Within the
TS group, these parameters did not differ between chil-
dren/adolescents and adults. Within the healthy control
group, IL1-ra differed significantly between healthy chil-
dren/adolescents and healthy adults; none of the other
parameters differed between these two subgroups. Sig-
nificant differences were found between healthy and TS
children/adolescents for TNF-alpha, IL1-ra, and sCD14
and between healthy and TS adults for IL-1-ra, sCD14,
and neopterin. Some of the subgroups were small, and
the results have to be interpreted accordingly.
The neopterin concentration correlated significantly
and positively with age in the patient group (r=0.355,
p=0.02). None of the parameters correlated significantly
with tic severity.
Discussion
There is growing evidence that immunological mechan-
isms contribute to the pathophysiology of TS, at least in
a subgroup of TS patients. We hypothesized that TS has
a common underlying immune mechanism that possibly
causes a disturbed clearing of infectious agents. As in-
nate immunity plays an important role in the first-line
immune response, in our study we focused on mono-
cytes/macrophages and associated parameters.
Our results are in line with previous findings: Leckman
et al. [19] reported signs of an increased activation of the
cellular type-1 immune response in TS. At baseline, the
authors found higher concentrations in TS patients than
in controls of both the T cell (type 1) cytokine IL-12 and
monocyte-derived TNF-alpha; the latter finding was in
contrast to our findings. Even higher concentrations of
these parameters were found in patients in a state of
symptom exacerbation. Interestingly, these observations
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patients. Leckman et al. found no differences in the
levels of other cytokines such as IL-1, IL-4, IL-6, IL-10,
and IFN-γ [19]. In our sample, TNF-alpha serum levels
were lower in TS patients than in healthy controls. Be-
sides methodological differences, several factors could
explain the differences between our findings. For ex-
ample, our sample had a higher number of unmedicated
patients. Our medicated patients received mainly dopa-
mine antagonists, whereas patients in the study by Leck-
man et al. received mainly alpha-agonists. Certain
antipsychotics are known to increase TNF-alpha levels
[36], so our sample may have actually had even lower
TNF-alpha levels if they had been in an unmedicated
state. Although our sample size was limited, and the sub-
groups were particularly small, we did not find a signifi-
cant influence of medication on any parameters,
including TNF-alpha. Another contributing factor could
be age [37] and disease stage. In our sample one limita-
tion was the age range of study participants. This is why
subanalyses were performed: healthy children/adoles-
cents showed the highest serum TNF-alpha levels, fol-
lowed by healthy adults, TS children/adolescents, and TS
adults. When the subgroup of TS children/adolescents
and TS adults were compared with the respective healthy
control age groups, differences were seen between both
age groups in almost all parameters. Given the high co-
morbidity of OCD and TS [23], our results in regard to
TNF-alpha levels are in accordance with reports of
decreased TNF-alpha levels in OCD [20-22]. In our sam-
ple, the subgroup analysis of patients with and those
without co-morbid OCD symptoms revealed no signifi-
cant difference in the levels of any of the determined
parameters, including TNF-alpha. This result indicates
that in our sample the occurrence of co-morbid OCD
seems to have no relevant influence on TNF-alpha levels.
The same is true for other parameters, although the
small size of the samples limits the interpretation of the
findings. However, the trend of stronger effects in the
comparison of healthy controls with TS patients with co-
morbid ODC is noteworthy and in parallel with the find-
ings of Gabbay et al. concerning IL-12 [24]. It has to be
mentioned that in our study the subgroups of TS
patients and TS patients with OCD could eventually suf-
fer from a co-morbid ADHD. The structured clinical
interviews did not show hints for ADHD in all study par-
ticipants, however, in order to exclude ADHD entirely, a
specific ADHD rating scale should be applied in future
studies. Another limitation of this study is that the used
rating scales (MOCI and TSGS) are reliable, but are less
frequently used then for example the Yale-Brown Obses-
sive Compulsive Scale and do not represent the ‘gold
standard’. In the present sample the mean value for
OCD in the TS group was 13 out of a maximum of 30.
Therefore these patients suffered only from a relatively
mild OCD. More homogeneous patient samples and fur-
ther studies are required to answer the question whether
Table 2 Concentrations of immune parameters and
monocyte markers in TS and healthy controls
Variable Group Mean±SD Rank sum z-value p-value*
Monocytes/nl Patients 0.57±0.22 50.1 −2.152 0.031
Controls 0.47±0.11 38.37
TNF-alpha pg/ml Patients 0.43±0.18 33.09 −2.421 0.015
Controls 0.56±0.25 45.39
IL-6 pg/ml Patients 1.89±1.71 39.41 −1.215 n.s.
Controls 1,74±1,64 33.43
IL1-ra ng/ml Patients 0.03±0.09 36.11 −2.813 0.005
Controls 0.04±0.06 51.24
sCD14 ng/ml Patients 6.37±1.43 30.25 −4.934 <0.0001
Controls 8.40±2.00 56,68
CRP mg/dl Patients 0.43±0.27 45.53 −2.013 0.044
Controls 0.37±0.37 37.85
Neopterin nmol/l Patients 6.03±2.19 48.51 −2.084 0.037
Controls 5.19±1.84 37.36
SD=standard deviation, n.s. = not significant; *Mann–Whitney U Test.
Table 1 Demographic features and clinical characteristics of TS patients and healthy controls
n TS patients n Healthy controls
Age, mean±SD (range) 46 29.3±14.1 (8–62) 43 30.6±13.8 (8–62)
< 18 years, n (%) 15 33% 10 23%
Age of onset, mean±SD (range) 46 8.2±3.7 (2–17) 43 n.a.
Male:female ratio (n) 46 3.6:1 (36 m, 10 f) 43 2.3:1 (30 m, 13 f)
TSGS values, mean±SD (range) 46 40.2±13.0 (16.8 - 64.3) 43 n.a.
OCD, n (%), MOCI ≥12,mean±SD (range) 34 74%13.1±2.8 (12–26) 0 0%
No OCD n (%), MOCI<12mean±SD (range) 12 26%0.42±0.79 (0–2) 43 100%1.42±0.96 (0–4)
Psychotropic medication
1, n (%) 30 65% 0 0%
Not medicated 16 35% 43 100%
TS=Tourette’s syndrome, OCD=obsessive compulsive disorder, MOCI=Maudsley Obsessive-Compulsive Inventory, TSGS=Tourette’s Syndrome Global Scale,
n=number, f=female, m=male, SD=standard deviation, n.a. = not applicable.
1including neuroleptics (n=18), tiapride (n=11) and antidepressants (n=7).
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as spectrum disorders with common causes or different
pathophysiological mechanisms.
Since cytokines have to be seen as a network [38],
TNF-alpha levels have to be discussed within the context
of our other findings. Also, the decreased levels of IL1-ra
suggest a decreased release of monocyte-derived cyto-
kines and point to a decreased production of IL-1. Since
IL-1 is released in a paracrine manner, the levels of cir-
culating IL-1 in the blood often are below the limit of
Table 4 Analysis of TNF-alpha, sCD14, IL1-ra, and neopterin in age subgroups
TNF-alpha IL1-ra sCD14 Neopterin
(pg/ml) (ng/ml) (ng/ml) (nmol/l)
Healthy mean±SD 0.67±0.24 0.056±0.051 8.0±1.4 4.70±1.09
children vs. rank sum 24.00 29.45 18.89 18.80
healthy mean±SD 0.51±0.23 0.035±0.058 8.6±2.1 5.31±1.90
adults rank sum 17.15 19.02 21.59 22.34
p-value* (n) n.s. (10/27) 0.017 (10/32) n.s. (9/32) n.s. (10/32)
TS children mean±SD 0.46±0.20 0.056±0.136 6.3±1.0 5.35±1.79
vs. rank sum 22.50 25.07 20.37 17.54
TS adults mean±SD 0.41±0.18 0.014±0.096 6.6±1.6 6.32±2.07
rank sum 19.42 21.17 23.60 24.16
p-value* (n) n.s. (14/26) n.s. (15/29) n.s. (15/29) n.s. (14/29)
Healthy mean±SD 0.67±0.24 0.056±0.051 8.0±1.4 4.70±1.09
children vs. rank sum 16.00 17.05 17.72 11.25
TS children mean±SD 0.46±0.20 0.056±0.136 6.3±1.0 5.35±1.79
rank sum 10.00 10.30 9.37 13.39
p-value* (n) 0.042 (10/14) 0.023 (10/15) 0.003 (9/15) n.s. (10/14)
Healthy adults mean±SD 0.51±0.23 0.035±0.058 8.6±2.1 5.31±1.90
vs. rank sum 30.54 35.48 39.48 26.20
TS adults mean±SD 0.41±0.18 0.014±0.096 6.6±1.6 6.32±2.07
rank sum 23.33 26.05 21.64 36.29
p-value* (n) n.s. (27/26) 0.038 (32/29) 0.000 (32/29) 0.027 (32/29)
TS=Tourette’s syndrome, n=number, SD=standard deviation, n.s. = not significant, *Mann–Whitney U Test.
Table 3 Analysis of TNF-alpha, sCD14, IL1-ra, and neopterin in co-morbid OCD subgroups
TNF-alpha sCD14 IL1-ra Neopterin
(pg/ml) (ng/ml) (ng/ml) (nmol/l)
TS without OCD mean±SD 0.52±0.17 6.9±1.3 0.013±0.014 5.10±1.28
vs. rank sum 18.82 21.05 22.25 16.50
TS with OCD mean±SD 0.40±0.18 6.3±1.4 0.034±0.095 6.36±2.15
rank sum 26.28 26.38 22.59 24.13
p-value* (n) n.s. (9/31) n.s. (12/32) n.s. (12/32) n.s. (12/31)
Control vs. mean±SD 0.55±0.24 8.4±2,0 0.041±0.057 5.16±1.75
TS with OCD rank sum 40.49 47.67 42.73 31.69
mean±SD 0.40±0.18 6.3±1.4 0.034±0.095 6.36±2.15
rank sum 27.35 23.33 30.64 44.19
p-value* (n) 0.006 (37/31) 0.000 (41/32) 0.016 (42/32) 0.013 (42/31)
Control vs. mean±SD 0.55±0.24 8.4±2.0 0.041±0.057 5.16±1.75
TS without OCD rank sum 23.91 30.01 30.01 27.17
mean±SD 0.52±0.17 6.9±1.3 0.013±0.014 5.10±1.28
rank sum 21.83 16.71 18.71 28.67
p-value* (n) n.s. (37/9) 0.009 (41/12) 0.028 (42/12) n.s. (42/12)
TS=Tourette’s syndrome, OCD=obsessive compulsive disorder, n=number, SD=standard deviation, n.s. = not significant, *Mann–Whitney U Test.
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fore, the validity of estimating IL-1 serum levels is critic-
ally discussed. IL1-ra is a more stable and reliable
laboratory parameter. It is produced and released from
activated cells of the monocyte lineage [39]. No differ-
ences in IL-6 levels were detected between TS patients
and healthy controls. IL-6 is assigned pro- and anti-
inflammatory characteristics and plays a key role in the
acute phase response, especially in direct resolutions of
acute infections and septic shock. It is likely to play a
detrimental role in chronic disease [40].
The most prominent finding—the lower levels of
sCD14 in TS—could also reflect a decreased monocyte
activation state and a possible susceptibility to infectious
agents. The reduced sCD14 levels in TS patients may
point to a blunted innate immunity and could indicate
incomplete elimination of infectious agents and a
chronic latent infectious state in TS. The most common
and sensitive marker of inflammation is CRP. Although
CRP levels were within the normal range in our sample
of TS patients, the distinct but significant increase com-
pared to controls could point to a latent underlying in-
flammatory process, similar to the role of high sensitivity
CRP in the pathogenesis of atherosclerosis [41]. Neop-
terin, an unspecific marker of inflammation found in
various inflammatory conditions such as infection and
autoimmune syndromes [42], has been used as a meas-
ure of cell-mediated immunity [43]. The higher levels of
neopterin in the TS group in our study reflects the acti-
vation of a Th-1 or type-1 immune response, since the
type-1 cytokine Interferon-γ (INF-γ) induces neopterin
production [44]. The findings of increased neopterin
values in TS patients in our study are in line with previ-
ous findings. Hoekstra et al. reported significantly ele-
vated neopterin levels in TS patients, indicating an
immune activation [45].
In summary, our results point to changes in innate im-
munity in TS patients compared with healthy controls:
sCD14 and the products of activated monocytes, TNF-
alpha, and IL1-ra showed lower levels. The number of cir-
culating monocytes, however, was increased. Whether this
increase in monocytes might be a compensatory mechan-
ism cannot be determined on the basis of the present data
and needs to be investigated in future studies. These
changes suggest a dysregulated immune system in TS,
which could have implications for susceptibility to infec-
tions or autoimmunity.
In our study, not just one but several different para-
meters showed results pointing to the under-activation
of components of the monocyte lineage associated with a
possible subclinical inflammatory reaction. Moreover, the
findings result from different laboratory methods, i.e. an
immunoassay technique, the Luminex bead technology,
and automated analyzer methods. As a caveat, it has to
be noted that TNF-alpha, IL-6, IL1-ra, CRP, and neop-
terin serum levels were within the normal ranges and
often close to the detection limits. Therefore, the
increases or decreases in relation to the control group
can only be interpreted as clues for potential trends. No
functional tests were performed, and the data reflect only
a single time point measurement of the peripheral im-
mune system. Nevertheless, little is known about immu-
nopathological mechanisms in TS, so that these
preliminary data contribute to the understanding of
monocyte regulation and innate immunity in TS.
To build a possible bridge between the peripheral im-
mune system and the nervous system, one interesting fact
is that microglia cells derive from the monocyte/macro-
phage lineage. Furthermore, cerebral hyperintensities in
magnetic resonance images, which can be a sign of neu-
roinflammatory processes, seem to be associated with TS
[46]. However, it remains unclear whether tic symptoms
are partly due to the damage caused directly by infections
or by the generated autoantibodies, or both, or due to
changes in the immune balance. In both cases, neuronal
signaling would be disturbed and could lead to tics. The
central dopamine systems are most likely to play an im-
portant role in TS and can be modulated by immune func-
tion. In their review, Martino et al. [4] propose a
pathophysiological model for immune-mediated dopamine
synthesis via CaM kinase II activation. In this model, infec-
tions might induce cross-reactive anti-neural antibodies.
First-line inflammatory responses might be promoted by
infections and may potentiate dopamine release by auto-
nomic fibers and modulate peripheral immune cells.
The immune constellation in our sample could be in ac-
cordance with an impaired innate immune response, asso-
ciated with an imbalance of the specific (type-1 and type-2)
immune responses, the type-2 responses possibly leading
to infections, autoimmune phenomena, and inflammatory
reactions. Nevertheless, one must take into account that
TS is a heterogeneous syndrome that may have different
underlying pathological mechanisms. The limited size of
our sample—in particular with respect to interfering vari-
ables such as age, medication and co-morbidity—means
that further intense research regarding the role of inflam-
mation, infection, and the immune system in TS is
required. Particularly functional tests and the analysis of
genetic polymorphisms that encode for inflammatory cyto-
kines or sCD14 would be of interest.
Conclusions
The present findings point to monocyte dysregulation in
TS. This possible dysbalance in innate immunity could
lead to a higher susceptibility to infectious agents and a
chronically latent inflammatory state in TS or could pre-
dispose to autoimmunity.
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